Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model
Open Access
- 3 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neuroscience
Abstract
The pathological hallmark of multiple sclerosis (MS) is the formation of multifocal demyelinating lesions in the central nervous system (CNS). Stimulation of innate receptors has been shown to suppress experimental autoimmune encephalomyelitis (EAE), an MS-like disease in mice. Specifically, targeting Toll-like receptor 9 (TLR9) and NOD-like receptor 2 (NOD2) significantly reduced disease severity. In the present work we have developed a novel focal EAE model to further study the effect of innate signaling on demyelinating pathology. Focal lesions were induced by stereotactic needle insertion into the corpus callosum (CC) of mice previously immunized for EAE. This resulted in focal pathology characterized by infiltration and demyelination in the CC. We find that intrathecal delivery of MIS416, a TLR9 and NOD2 bispecific innate ligand, into the cerebrospinal fluid reduced focal lesions in the CC. This was associated with upregulation of type I and II interferons, interleukin-10, arginase-1, CCL-2 and CXCL-10. Analysis of draining cervical lymph nodes showed upregulation of type II interferons and interleukin 10. Moreover, intrathecal MIS416 altered the composition of early CNS infiltrates, increasing proportions of myeloid and NK cells and reducing T cells at the lesion site. This study contributes to an increased understanding of how innate immune responses can play a protective role, which in turn may lead to additional therapeutic strategies for the prevention and treatment of demyelinating pathologies.Funding Information
- Det Frie Forskningsråd (8020-00157B)
- Lundbeckfonden (R209-2015-2774)
- Scleroseforeningen
- Warwara Larsens Fond
- Augustinus Fonden
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
This publication has 32 references indexed in Scilit:
- Multiple sclerosisNature Reviews Disease Primers, 2018
- Myeloid derived suppressor cells and autoimmunityHuman Immunology, 2016
- Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and diseaseBrain, Behavior, and Immunity, 2016
- Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis modelJournal of Neuroimmunology, 2015
- Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple SclerosisFrontiers in Immunology, 2015
- Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune SystemPLOS ONE, 2012
- Axonal Damage in Multiple SclerosisMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011
- Interferon-β Treatment for Multiple SclerosisNeurotherapeutics, 2007
- The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous systemThe FASEB Journal, 2006
- Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosisJournal of the Neurological Sciences, 1997